tivantinib

1 stories · following the connections

Business

Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib in Second-Line Hepatocellular Carcinoma

By Nasdaq OMXMar 22, 2016, 11:30 AM UTC